A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

A Phase 2, 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

This phase 2 study is a placebo-controlled, double-blind, parallel group study of four concentrations of SM04690 (0.03, 0.07, 0.15, and 0.23 mg per 2 mL injection) injected intraarticularly (IA) into the target knee joint of subjects with moderately to severely symptomatic osteoarthritis (OA). Based on previous studies of SM04690, key phenotypes of laterality (unilateral vs bilateral) as well as chronic pain (as measured by the Widespread Pain Index) were identified as confounding variables impacting the overall assessment of both radiologic and clinical efficacy outcomes. The design of SM04690-OA-04 is based upon previous study designs while assessing strategies to combat the confounding impact of laterality and chronic pain. To evaluate the effect of IA vehicle injection on patient-reported outcomes (PRO) such as pain, stiffness, and function in OA, this study also includes one cohort that receives a 2 mL IA injection of vehicle (placebo), and one cohort that receives a sham injection (i.e., a needle stick with 0 mL vehicle injected).

Study Overview

• Status: Completed
• Conditions: Knee Osteoarthritis
• Intervention / Treatment: Drug: SM04690; Other: Placebo; Other: Sham

• Study Type: Interventional
• Enrollment (Actual): 700
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Anniston, Alabama, United States, 36207
      • Research Site
    • Birmingham, Alabama, United States, 35216
      • Research Site
    • Mobile, Alabama, United States, 36608
      • Research Site
  • Arizona
    • Chandler, Arizona, United States, 85224
      • Research Site
    • Phoenix, Arizona, United States, 85018
      • Research Site
    • Phoenix, Arizona, United States, 85053
      • Research Site
    • Tucson, Arizona, United States, 85712
      • Research Site
  • California
    • Anaheim, California, United States, 92801
      • Research Site
    • Canoga Park, California, United States, 91303
      • Research Site
    • Carmichael, California, United States, 95608
      • Research Site
    • Cerritos, California, United States, 90703
      • Research Site
    • El Cajon, California, United States, 92020
      • Research Site
    • Gold River, California, United States, 95670
      • Research Site
    • La Mesa, California, United States, 91942
      • Research Site
    • Los Angeles, California, United States, 90036
      • Research Site
    • Rancho Mirage, California, United States, 92270
      • Research Site
    • Sacramento, California, United States, 95817
      • Research Site
    • San Diego, California, United States, 92103
      • Research Site
    • San Marcos, California, United States, 92078
      • Research Site
    • Spring Valley, California, United States, 91978
      • Research Site
  • Colorado
    • Boulder, Colorado, United States, 80301
      • Research Site
  • Connecticut
    • Stamford, Connecticut, United States, 06905
      • Research Site
    • Trumbull, Connecticut, United States, 06606
      • Research Site
    • Waterbury, Connecticut, United States, 06708
      • Research Site
  • Florida
    • Clearwater, Florida, United States, 33761
      • Research Site
    • Coral Gables, Florida, United States, 33134
      • Research Site
    • DeLand, Florida, United States, 32720
      • Research Site
    • Edgewater, Florida, United States, 32132
      • Research Site
    • Lauderdale Lakes, Florida, United States, 33319
      • Research Site
    • Miami, Florida, United States, 33143
      • Research Site
    • Pinellas Park, Florida, United States, 33781
      • Research Site
  • Georgia
    • Marietta, Georgia, United States, 30060
      • Research Site
    • Woodstock, Georgia, United States, 30189
      • Research Site
  • Illinois
    • Chicago, Illinois, United States, 60607
      • Research Site
  • Indiana
    • Evansville, Indiana, United States, 47714
      • Research Site
  • Kansas
    • Newton, Kansas, United States, 67114
      • Research Site
    • Prairie Village, Kansas, United States, 66208
      • Research Site
    • Wichita, Kansas, United States, 67205
      • Research Site
  • Kentucky
    • Lexington, Kentucky, United States, 40504
      • Research Site
  • Louisiana
    • Jefferson, Louisiana, United States, 70121
      • Research Site
  • Maryland
    • Frederick, Maryland, United States, 21702
      • Research Site
  • Massachusetts
    • Boston, Massachusetts, United States, 02111
      • Research Site
  • Michigan
    • Troy, Michigan, United States, 48085
      • Research Site
  • Missouri
    • Kansas City, Missouri, United States, 64114
      • Research Site
    • Saint Louis, Missouri, United States, 63141
      • Research Site
    • Saint Peters, Missouri, United States, 63303
      • Research Site
  • Nebraska
    • Lincoln, Nebraska, United States, 68516
      • Research Site
  • Nevada
    • Las Vegas, Nevada, United States, 89119
      • Research Site
  • New Mexico
    • Albuquerque, New Mexico, United States, 87102
      • Research Site
  • New York
    • Rochester, New York, United States, 14609
      • Research Site
  • North Carolina
    • Charlotte, North Carolina, United States, 28209
      • Research Site
    • Charlotte, North Carolina, United States, 28210
      • Research Site
    • High Point, North Carolina, United States, 27262
      • Research Site
    • Salisbury, North Carolina, United States, 28144
      • Research Site
    • Wilmington, North Carolina, United States, 28401
      • Research Site
  • North Dakota
    • Fargo, North Dakota, United States, 58103
      • Research Site
  • Ohio
    • Cincinnati, Ohio, United States, 45246
      • Research Site
    • Cincinnati, Ohio, United States, 45224
      • Research Site
    • Cleveland, Ohio, United States, 44122
      • Research Site
    • Columbus, Ohio, United States, 43213
      • Research Site
  • Pennsylvania
    • Duncansville, Pennsylvania, United States, 16635
      • Research Site
    • Philadelphia, Pennsylvania, United States, 19152
      • Research Site
    • State College, Pennsylvania, United States, 16801
      • Research Site
  • South Carolina
    • Charleston, South Carolina, United States, 29406
      • Research Site
    • Mount Pleasant, South Carolina, United States, 29464
      • Research Site
  • South Dakota
    • Rapid City, South Dakota, United States, 57702
      • Research Site
  • Texas
    • Austin, Texas, United States, 78745
      • Research Site
    • Bedford, Texas, United States, 76021
      • Research Site
    • Dallas, Texas, United States, 75231
      • Research Site
    • Houston, Texas, United States, 77055
      • Research Site
    • San Angelo, Texas, United States, 76904
      • Research Site
  • Virginia
    • Arlington, Virginia, United States, 22207
      • Research Site
    • Charlottesville, Virginia, United States, 22911
      • Research Site
    • Danville, Virginia, United States, 24541
      • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Ambulatory
• Diagnosis of femorotibial OA in the target knee by standard American College of Rheumatology (ACR) criteria at screening (clinical AND radiographic criteria); OA of the knee is not to be secondary to any rheumatologic conditions (e.g., rheumatoid arthritis)
• Pain compatible with OA of the knee(s) for at least 26 weeks prior to screening
• Primary source of pain throughout the body is due to OA in the target knee
• Willingness to use an electronic diary on a daily basis in the evening for the screening period and 24-week study duration
• Negative drug test for opioids and drugs of abuse, except alcohol and marijuana, at screening
• Subjects with depression or anxiety must be clinically stable for 12 weeks prior to screening, and, if on treatment for depression or anxiety, be on 12 weeks of stable therapy
• Full understanding of the requirements of the study and willingness to comply with all study visits and assessments
• Subjects must have read and understood the informed consent form, and must have signed it prior to any study-related procedure being performed

Exclusion Criteria:

• Women who are pregnant, lactating, or have a positive pregnancy result at screening
• Women of child bearing potential who are sexually active and are not willing to use a highly effective method of birth control during the study period
• Males who are sexually active and have a partner who is capable of becoming pregnant, neither of whom have had surgery to become sterilized or whom are not using a highly effective method of birth control
• Body mass index (BMI) > 35
• Partial or complete joint replacement in either knee
• Currently requires regular use of ambulatory assistive devices (e.g., wheelchair, parallel bars, walker, canes, or crutches) or use of a lower extremity prosthesis, and/or a structural knee brace
• Previous participation in a Samumed clinical trial investigating SM04690
• Any surgery (e.g., arthroscopy) in either knee within 26 weeks prior to screening
• Any planned surgery during the study period
• History of malignancy within the last 5 years; however, subjects with prior history of in situ cancer or basal or squamous cell skin cancer are eligible if completely excised. Subjects with other malignancies are eligible if they have been continuously disease free for at least 5 years prior to any study injection
• Comorbid conditions that could affect study endpoint assessments of the target knee, including, but not limited to, rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, gout or pseudogout, and fibromyalgia
• Any diagnosed psychiatric condition that includes, but is not limited to, a history of mania, bipolar disorder, psychotic disorder, schizophrenia, schizoaffective disorder, major depressive disorder, or generalized anxiety disorder
• Participation in a clinical research trial that included the receipt of an investigational product or any experimental therapeutic procedure, or an observational research trial related to osteoarthritis within 8 weeks prior to any study injection, or planned participation in any such trial
• Treatment of the target knee with intra-articular glucocorticoids (e.g., methylprednisolone) within 12 weeks prior to screening
• Any intra-articular injection into the target knee with a therapeutic aim including, but not limited to, viscosupplementation (e.g., hyaluronic acid), platelet-rich plasma (PRP), and stem cell therapies within 24 weeks prior to screening; treatment of the target knee with intra-articular glucocorticoids greater than 12 weeks prior to screening is allowed
• Treatment with systemic glucocorticoids greater than 10 mg prednisone or the equivalent per day within 4 weeks prior to screening
• Effusion of the target knee clinically requiring aspiration within 12 weeks prior to screening
• Use of electrotherapy, acupuncture, and/or chiropractic treatments for knee OA within 4 weeks prior to screening
• Any known active infections, including urinary tract infection, upper respiratory tract infection, sinusitis, suspicion of intra-articular infection, hepatitis B or hepatitis C infection, and/or infections that may compromise the immune system such as human immunodeficiency virus (HIV) at study start
• Use of centrally acting analgesics (e.g., duloxetine) within 12 weeks prior to screening
• Use of anticonvulsants within 12 weeks prior to screening, unless used for seizure or migraine prophylaxis
• Subjects requiring the usage of opioids >1x per week within 12 weeks prior to screening
• Use of topical local anesthetic agents (gels, creams, or patches such as the Lidoderm patch) for the treatment of knee OA within 7 days of screening

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 0.07 mg SM04690; Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle	Drug: SM04690; Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
Experimental: 0.03 mg SM04690; Single intra-articular injection of 0.03 mg SM04690 in 2 mL vehicle	Drug: SM04690; Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
Experimental: 0.15 mg SM04690; Single intra-articular injection of 0.15 mg SM04690 in 2 mL vehicle	Drug: SM04690; Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
Experimental: 0.23 mg SM04690; Single intra-articular injection of 0.23 mg SM04690 in 2 mL vehicle	Drug: SM04690; Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
Placebo Comparator: Placebo; Single intra-articular injection of 0 mg SM04690 in 2 mL vehicle	Other: Placebo; Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
Sham Comparator: Sham; Single intra-articular injection of 0 mg SM04690 in 0 mL vehicle	Other: Sham; Healthcare professional-administered intra-articular injection performed once on Day 1 of the study

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline Osteoarthritis (OA) Pain in the Target Knee as Assessed by the Weekly Average of Daily Pain Numeric Rating Scale (NRS)	Change from baseline OA pain in the target knee as assessed by the weekly average of daily pain NRS at Week 24. The pain NRS is an 11-point scale [0-10] for subject self-reporting of average knee pain in the last 24 hours; 0 indicates no pain, and 10 represents the worst possible pain (pain as bad as one can imagine).	Baseline and Week 24
Change From Baseline OA Pain in the Target Knee as Assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscore (WOMAC Pain)	Change from baseline OA pain in the target knee as assessed by WOMAC Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 24. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore is standardized and reported ranging from 0 to 100 [0 = no pain; 100 = pain as bad as it can be].	Baseline and Week 24
Change From Baseline OA Function in the Target Knee as Assessed by WOMAC Physical Function Subscore (WOMAC Function)	Change from baseline OA function in the target knee as assessed by WOMAC Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 24. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore is standardized and reported ranging from 0 to 100 [0 = no functional disability, 100 = unable to function].	Baseline and Week 24
Change From Baseline in Medial Joint Space Width (mJSW) of the Target Knee	Change from baseline in mJSW as documented by radiograph of the target knee.	Baseline and Week 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline OA Disease Activity as Assessed by Patient Global Assessment (PtGA)	Change from baseline OA disease activity as assessed by PtGA at Week 24. The PtGA was completed using a 100 mm visual analog scale (VAS) adapted from the Patient Assessment Form © 1999, American College of Rheumatology. The subject rated how well he/she was doing, considering all the ways in which illness and health conditions may affected him/her. The VAS scale was anchored by "Very Well" on the left (scored as 0) and "Very Poorly" on the right (scored as 100). Higher scores indicated poorer disease assessment by the subject.	Baseline and Week 24

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline OA Pain in the Target Knee as Assessed by WOMAC Pain Subscore (WOMAC Pain)	Change from baseline OA pain in the target knee as assessed by WOMAC Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 12. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore is standardized and reported ranging from 0 to 100 [0 = no pain, 100 = pain as bad as it can be].	Baseline and Week 12
Change From Baseline OA Function in the Target Knee as Assessed by WOMAC Physical Function Subscore (WOMAC Function)	Change from baseline OA function in the target knee as assessed by WOMAC Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 12. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore is standardized and reported ranging from 0 to 100 [0 = no functional disability, 100 = unable to function].	Baseline and Week 12
Change From Baseline OA Pain in the Target Knee as Assesses by the Weekly Average of Daily Pain NRS	Change from baseline OA pain in the target knee as assessed by the weekly average of daily pain NRS at Week 12. The pain NRS is an 11-point scale [0-10] for subject self-reporting of average knee pain in the last 24 hours; 0 indicates no pain, and 10 represents the worst possible pain (pain as bad as one can imagine).	Baseline and Week 12
Change From Baseline OA Disease Activity as Assessed by Patient Global Assessment (PtGA)	Change from baseline OA disease activity as assessed by PtGA at Week 12. The PtGA completed using a 100 mm visual analog scale (VAS) adapted from the Patient Assessment Form © 1999, American College of Rheumatology. The subject rated how well he/she was doing, considering all the ways in which illness and health conditions may affected him/her. The VAS scale was anchored by "Very Well" on the left (scored as 0) and "Very Poorly" on the right (scored as 100). Higher scores indicated poorer disease assessment by the subject.	Baseline and Week 12

Collaborators and Investigators

• Sponsor: Biosplice Therapeutics, Inc.

Publications and helpful links

General Publications

• Yazici Y, McAlindon TE, Gibofsky A, Lane NE, Lattermann C, Skrepnik N, Swearingen CJ, Simsek I, Ghandehari H, DiFrancesco A, Gibbs J, Tambiah JRS, Hochberg MC. A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis. Osteoarthritis Cartilage. 2021 May;29(5):654-666. doi: 10.1016/j.joca.2021.02.004. Epub 2021 Feb 12.
• Tambiah JRS, Simsek I, Swearingen CJ, Kennedy S, Cole BJ, McAlindon TE, Yazici Y. Comparing Patient-Reported Outcomes From Sham and Saline-Based Placebo Injections for Knee Osteoarthritis: Data From a Randomized Clinical Trial of Lorecivivint. Am J Sports Med. 2022 Mar;50(3):630-636. doi: 10.1177/03635465211067201. Epub 2022 Jan 10.
• Tambiah JRS, Kennedy S, Swearingen CJ, Simsek I, Yazici Y, Farr J, Conaghan PG. Individual Participant Symptom Responses to Intra-Articular Lorecivivint in Knee Osteoarthritis: Post Hoc Analysis of a Phase 2B Trial. Rheumatol Ther. 2021 Jun;8(2):973-985. doi: 10.1007/s40744-021-00316-w. Epub 2021 Jun 8.

Study record dates

Study Major Dates

• Study Start (Actual): April 24, 2017
• Primary Completion (Actual): April 30, 2018
• Study Completion (Actual): April 30, 2018

Study Registration Dates

• First Submitted: April 18, 2017
• First Submitted That Met QC Criteria: April 20, 2017
• First Posted (Actual): April 21, 2017

Study Record Updates

• Last Update Posted (Actual): June 11, 2021
• Last Update Submitted That Met QC Criteria: May 20, 2021
• Last Verified: May 1, 2021

More Information

Terms related to this study

• Keywords: osteoarthritis; Samumed; SM04690; Wnt pathway inhibitor
• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Osteoarthritis; Osteoarthritis, Knee; Anti-Inflammatory Agents; Lorecivivint
• Other Study ID Numbers: SM04690-OA-04

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No